This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (13)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Review  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic

Effect of Recent Clinical Trials

Jeffrey J. Goldberger, MD

Arch Intern Med. 1999;159:1281-1287.

Tremendous strides have been made in recent years in the treatment and prevention of sudden cardiac death. Large scale trials have now established several interventions that may improve survival in patients susceptible to sudden cardiac death. In patients who have had a sustained ventricular tachyarrhythmia, the current therapy of choice is an implantable cardioverter defibrillator. For prophylaxis of sudden cardiac death in patients without a previous event, several approaches should be considered. -Adrenergic blocking agents are an effective pharmacologic therapy in patients following myocardial infarction, and their efficacy has also most recently been demonstrated in patients with congestive heart failure. There is no Vaughan Williams class I or III antiarrhythmic drug that has demonstrated efficacy as a prophylactic agent to reduce mortality in these populations, with the possible exception of amiodarone. The best therapeutic approach for prophylactic therapy to prevent sudden cardiac death appears to be the implantable cardioverter defibrillator; however, its use can be justified only in patients at high risk for developing sudden cardiac death. Further work is needed to identify the high risk populations in which this therapy is warranted.

From the Division of Cardiology, Department of Medicine, Northwestern University Medical School, and Northwestern Memorial Hospital, Chicago, Ill.

RELATED ARTICLE

Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 1999;159(12):1378.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Acute ischaemia as a trigger of sudden cardiac death
Thygesen and Uretsky
Eur Heart J Suppl 2004;6:D88-D90.
ABSTRACT | FULL TEXT  

Keeping Your Patient With Heart Failure Safe: A Review of Potentially Dangerous Medications
Amabile and Spencer
Arch Intern Med 2004;164:709-720.
FULL TEXT  

Use of Sympathomimetic Drugs Leads to Increased Risk of Hospitalization for Arrhythmias in Patients With Congestive Heart Failure
Bouvy et al.
Arch Intern Med 2000;160:2477-2480.
ABSTRACT | FULL TEXT